Novavax's quarterly loss shrinks as it ramps down spending on COVID vaccines
Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 ...
Novavax sees royalties, reduced expenses on COVID vaccines from Sanofi partnership
Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...
Novavax execs lay out 2025 game plan, talk ‘defining moment’ for business
Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.
Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value
Novavax Inc (NASDAQ:NVAX) reported fourth-quarter 2024 sales of $88.31 million, compared to $291 million a year, beating the ...
cidrap.umn2d
COVID 2024-25 vaccines 33% protective against emergency room or urgent care visits, data reveal
Effectiveness of 2024-25 COVID-19 vaccination against a COVID-19–associated ED/UC visit was 33% (95% confidence interval [CI] ...
Novavax reports large quarterly revenue declines, rethinks its strategic direction
Novavax reported $88 million in revenues in the fourth quarter, compared to $291 million the year prior, and $682 million for ...
Novavax Q4 Earnings Review: Long-Term Downsizing Plan Suggests Sell Rating
Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...
McKnight's Long-Term Care News1d
Report: COVID-19 vaccine 33 percent effective at thwarting emergency, urgent care visits
The current COVID-19 vaccine is 33% effective at preventing emergency department or urgent care visits among adults of all ages. It also is 45% to 46% effective at preventing hospitalizations in older ...
Seeking Alpha6d
Novavax, Inc. (NVAX) Q4 2024 Earnings Call Transcript
The launch of our '24-'25 season updated COVID-19 vaccine in August. Novavax successfully operationalizing our partnership with Sanofi, which enabled them last month to assume lead commercial ...
COVID-like bat virus discovered by researchers in Chinese lab
Researchers at the Wuhan Institute of Virology in China said they discovered a new coronavirus in bats that enters cells ...
U.S. News & World Report7d
Novavax Sees Royalties, Reduced Expenses on COVID Vaccines From Sanofi Partnership
(Reuters) -Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi for COVID-19 vaccines to generate royalties, and reduce ...
Benzinga.com6d
Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value
The COVID-19 vaccine maker reported an earning loss of 51 cents per share, down from $1.44 a year ago, in line with the Wall Street Estimate. Also Read: Wegovy Maker Novo Nordisk To Buy Novavax ...